SMARCD1 Antibody

Introduction to SMARCD1 Protein

SMARCD1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily D, Member 1), also known as BAF60a or 60 kDa BRG-1/Brm-associated factor subunit A, is a 476 amino acid nuclear protein with a molecular weight of approximately 58 kDa . It is a key component of the mammalian SWI/SNF chromatin remodeling complex, which plays essential roles in altering DNA-histone contacts within nucleosomes in an ATP-dependent manner .

The protein contains a characteristic SWIB domain and is expressed ubiquitously, with notable expression in liver, brain, muscle, lung, kidney, pancreas, and placenta . SMARCD1 serves dual functions in gene regulation by participating in both transcriptional activation and repression of select genes through chromatin remodeling processes .

SMARCD1 is particularly important in developmental processes and cellular differentiation. It belongs to both neural progenitor-specific chromatin remodeling complex (npBAF complex) and neuron-specific chromatin remodeling complex (nBAF complex) . During neural development, a transition occurs between these complexes as cells progress from proliferating neural stem/progenitor cells to postmitotic neurons, requiring specific changes in the composition of these complexes .

SMARCD1 Protein Function

SMARCD1 mediates critical interactions between nuclear receptors and the BRG1/SMARCA4 chromatin-remodeling complex for transactivation . It exhibits a strong influence on vitamin D-mediated transcriptional activity from enhancer vitamin D receptor elements (VDREs) and may function as a link between mammalian SWI-SNF-like chromatin remodeling complexes and the vitamin D receptor (VDR) heterodimer . Additional research has revealed SMARCD1's interaction with AKIRIN2, suggesting further regulatory pathways .

SMARCD1 Antibody Types and Sources

SMARCD1 antibodies are available in various formats from multiple commercial suppliers, each optimized for specific research applications. These antibodies are typically categorized as either monoclonal or polyclonal and are raised in different host species.

Applications of SMARCD1 Antibodies

SMARCD1 antibodies have been validated for numerous research applications, enabling the investigation of this protein's expression, localization, interactions, and functions across different experimental settings.

Common Laboratory Applications

Table 2: Applications and Recommended Dilutions for SMARCD1 Antibodies

SMARCD1 antibodies have been extensively validated in diverse cell lines and tissue samples, including NIH/3T3 (mouse embryonic fibroblast), HeLa (human cervix adenocarcinoma), HEK-293T, A431 (human epidermoid carcinoma), and CACO-2 cells, as well as in human and mouse brain tissue and human lymphoma tissue .

Research Findings Using SMARCD1 Antibodies

SMARCD1 antibodies have been instrumental in elucidating the function and significance of this protein in various biological contexts and disease states. Key research findings highlight the importance of SMARCD1 in hematopoietic differentiation, cancer progression, and chromatin remodeling dynamics.

SMARCD1 in Hematopoietic Differentiation and Leukemia

Studies utilizing SMARCD1 antibodies have revealed that SMARCD1 expression is enriched in CD34+ hematopoietic stem/progenitor cells (HSPCs) and decreases during myeloid differentiation . This expression pattern is observed in both normal and leukemic cells, with higher expression in undifferentiated acute myeloid leukemia (AML) subtypes (M0, M1, M2) compared to more differentiated subtypes (M3, M4, M5) .

Co-immunoprecipitation experiments with SMARCD1 antibodies confirmed its association with the SWI/SNF complex in leukemic cells, providing mechanistic insights into its function . SMARCD1 was found to negatively regulate myeloid differentiation by maintaining a repressive chromatin state at promoters of myeloid differentiation genes. Knockdown of SMARCD1 in leukemic cell lines (HL-60 and U937) and in patient-derived CD34+ AML cells significantly enhanced myeloid differentiation, as evidenced by increased expression of differentiation markers (CD11b and CD14) and morphological changes consistent with differentiation .

Analysis of AML patient cohorts revealed that high SMARCD1 expression correlates with leukemic stem cell signatures and poor differentiation markers, while also associating with higher blast percentages and lower peripheral monocyte counts . These findings, facilitated by SMARCD1 antibodies, suggest potential therapeutic implications for targeting SMARCD1 in AML.

SMARCD1 as a "Goldilocks" Metastasis Modifier in Breast Cancer

Recent research using SMARCD1 antibodies has identified SMARCD1 as a "Goldilocks" metastasis modifier in breast cancer . Co-immunoprecipitation followed by proteomic analysis revealed SMARCD1's interactions in metastatic breast cancer cells . Notably, both high and low expression of SMARCD1 were associated with positive clinical outcomes, while intermediate expression significantly reduced survival probability, suggesting a discrete window of expression necessary for metastasis to occur .

Experimental modulation of SMARCD1 levels (knockdown or overexpression) in breast cancer cells did not affect basic cellular processes such as proliferation, colony formation, or migration, but significantly impacted tumorsphere formation, suggesting a role in cancer stem cell-like properties . ATAC-seq analysis demonstrated that SMARCD1 knockdown resulted in more regions of open chromatin compared to controls and overexpression cells, indicating its influence on chromatin accessibility .

Technical Considerations for SMARCD1 Antibody Use

Successful implementation of SMARCD1 antibodies in research applications requires attention to several technical considerations to ensure optimal results.

Sample Preparation and Detection Conditions

For Western blot applications, SMARCD1 antibodies typically detect a band at approximately 58 kDa, consistent with the predicted molecular weight of the protein . Various blocking and dilution buffers have been validated, with 5% non-fat dry milk in TBST being commonly used .

For immunohistochemistry applications, antigen retrieval methods have been optimized, with suppliers recommending either TE buffer (pH 9.0) or citrate buffer (pH 6.0) for optimal results . For immunofluorescence studies, PFA fixation and Triton X-100 permeabilization have been successfully employed .